Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Rating of "Moderate Buy" by Analysts

Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $13.25.A number of research firms recently commented on OBIO. Barclays decreased their price objective on shares of Orchestra BioMed from $12.00 to $11.00 and set an "overweight" rating on the stock in a report on Wednesday, November 12th. Weiss Ratings restated a "sell (e+)" rating on shares of Orchestra BioMed in a report on Wednesday, October 8th. HC Wainwright reduced their price objective on Orchestra BioMed from $12.00 to $10.00 and set a "buy" rating for the company in a report on Thursday, September 4th. Chardan Capital reiterated a "buy" rating and set a $20.00 target price on shares of Orchestra BioMed in a research report on Thursday, November 13th. Finally, BTIG Research restated a "neutral" rating on shares of Orchestra BioMed in a research report on Wednesday, August 20th.Get Orchestra BioMed alerts:View Our Latest Report on OBIOHedge Funds Weigh In On Orchestra BioMedA number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC lifted its position in shares of Orchestra BioMed by 9.2% in the third quarter. Citadel Advisors LLC now owns 54,002 shares of the company's stock valued at $134,000 after acquiring an additional 4,561 shares in the last quarter. Bank of America Corp DE increased its position in Orchestra BioMed by 35.7% during the 2nd quarter. Bank of America Corp DE now owns 21,577 shares of the company's stock worth $58,000 after purchasing an additional 5,678 shares in the last quarter. Deutsche Bank AG raised its stake in Orchestra BioMed by 67.3% in the 1st quarter. Deutsche Bank AG now owns 20,219 shares of the company's stock valued at $87,000 after purchasing an additional 8,134 shares during the last quarter. Catalyst Funds Management Pty Ltd purchased a new position in Orchestra BioMed in the 2nd quarter valued at about $31,000. Finally, Creative Planning purchased a new position in Orchestra BioMed in the 2nd quarter valued at about $40,000. Institutional investors and hedge funds own 53.20% of the company's stock. Orchestra BioMed Stock Down 0.2%Orchestra BioMed stock opened at $4.39 on Tuesday. The stock has a 50 day moving average of $3.93 and a two-hundred day moving average of $3.23. Orchestra BioMed has a twelve month low of $2.20 and a twelve month high of $6.30. The stock has a market capitalization of $247.90 million, a price-to-earnings ratio of -2.41 and a beta of 0.62. The company has a current ratio of 4.73, a quick ratio of 4.72 and a debt-to-equity ratio of 0.32. Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Orchestra BioMed had a negative return on equity of 320.09% and a negative net margin of 2,665.05%.The firm had revenue of $0.86 million for the quarter, compared to analysts' expectations of $0.74 million. As a group, research analysts expect that Orchestra BioMed will post -1.66 earnings per share for the current year. Orchestra BioMed Company Profile (Get Free Report)Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.Featured ArticlesFive stocks we like better than Orchestra BioMedBest of the list of Dividend Aristocrats: Build wealth with the aristocrat indexWhat Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer HealthWhy Are Stock Sectors Important to Successful Investing?3 Stocks Most Likely to Split in 2026Stock Average Calculator ChargePoint's Comeback Story: Why This EV Stock Is Charging Up AgainThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Orchestra BioMed Right Now?Before you consider Orchestra BioMed, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list.While Orchestra BioMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here